Elaine Mary Pascoe

Elaine Mary Pascoe has expertise in public health, nephrology and clinical trials.

Some of her publication include:

Journal Article: Representativeness of honeypot trial participants to Australasian PD patients
Zhang, Lei, Badve, Sunil V. , Pascoe, Elaine M., Beller, Elaine, Cass, Alan , Clark, Carolyn, de Zoysa, Janak, Isbel, Nicole M., Liu, Xusheng, McTaggart, Steven, Morrish, Alicia T., Playford, Geoffrey, Scaria, Anish, Snelling, Paul , Vergara, Liza A., Hawley, Carmel M. and Johnson, David W. (2017) Representativeness of honeypot trial participants to Australasian PD patients. Peritoneal Dialysis International, 37 5: 516-522. doi:10.3747/pdi.2016.00065

Journal Article: Association between peritoneal glucose exposure and peritonitis in peritoneal dialysis patients: the balANZ trial
Nataatmadja, Melissa, Cho, Yeoungjee, Pascoe, Elaine M., Darssan, Darsy, Hawley, Carmel M. and Johnson, David W. (2017) Association between peritoneal glucose exposure and peritonitis in peritoneal dialysis patients: the balANZ trial. Peritoneal Dialysis International, 37 4: 407-413. doi:10.3747/pdi.2016.00263

Journal Article: Association between serum hepcidin-25 and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial
Gummer, Joel, Trengove, Robert, Pascoe, Elaine M., Badve, Sunil V., Cass, Alan, Clarke, Philip, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M., Johnson, David W., Olynyk, John K. and Ferrari, Paolo (2017) Association between serum hepcidin-25 and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 22 7: 548-554. doi:10.1111/nep.12815